I
Innovent Biologics
Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies
At a glance
- Status
- Listed
- Listing
- IPO 2018
Open roles
Innovent Biologics in the Suzhou Shi ecosystem
The Innovent Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later19 investors entered at this stage
Legend Capital- LVLilly Asia Ventures
- ZCZhonghe Capital
- RCRock Springs Capital
- AGAlly Bridge Group
- SMSDIC Fund Management
- PCPing An Capital
- ACApricot Capital
Temasek
Hillhouse Capital- TITaikang Life Insurance
Cormorant Asset Management- CGCapital Group
- FBFrontline BioVentures
- CIChina Life Private Equity Investment
- PGPing An Group
- CCChina Shenzhen New Venture Capital
Eight Roads Ventures- S(State Development & Investment Corporation (SDIC)
Source: Dealroom Talent Intelligence.
Patents
151 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Innovent Biologics was the backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
2 deals across Innovent Biologics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Innovent Biologics's portfolio, mapped.
See Innovent Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Phrontline raises $40M Series A for bispecific ADC cancer drugs
Innovent's SINTBILO meets Phase 3 CREDIT-5 goal as first-line cholesterol-lowering monotherapy

